CDXS
Price
$2.23
Change
-$0.02 (-0.89%)
Updated
Jun 13 closing price
Capitalization
184.74M
46 days until earnings call
EPIX
Price
$1.67
Change
-$0.03 (-1.76%)
Updated
Jun 13 closing price
Capitalization
74.13M
52 days until earnings call
Interact to see
Advertisement

CDXS vs EPIX

Header iconCDXS vs EPIX Comparison
Open Charts CDXS vs EPIXBanner chart's image
Codexis
Price$2.23
Change-$0.02 (-0.89%)
Volume$720.21K
Capitalization184.74M
ESSA Pharma
Price$1.67
Change-$0.03 (-1.76%)
Volume$39.1K
Capitalization74.13M
CDXS vs EPIX Comparison Chart
Loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EPIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. EPIX commentary
Jun 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a StrongBuy and EPIX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 16, 2025
Stock price -- (CDXS: $2.23 vs. EPIX: $1.67)
Brand notoriety: CDXS and EPIX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 91% vs. EPIX: 23%
Market capitalization -- CDXS: $184.74M vs. EPIX: $74.13M
CDXS [@Biotechnology] is valued at $184.74M. EPIX’s [@Biotechnology] market capitalization is $74.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileEPIX’s FA Score has 1 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • EPIX’s FA Score: 1 green, 4 red.
According to our system of comparison, EPIX is a better buy in the long-term than CDXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 3 TA indicator(s) are bullish while EPIX’s TA Score has 1 bullish TA indicator(s).

  • CDXS’s TA Score: 3 bullish, 6 bearish.
  • EPIX’s TA Score: 1 bullish, 6 bearish.
According to our system of comparison, CDXS is a better buy in the short-term than EPIX.

Price Growth

CDXS (@Biotechnology) experienced а -5.91% price change this week, while EPIX (@Biotechnology) price change was -2.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.63%. For the same industry, the average monthly price growth was +13.05%, and the average quarterly price growth was +4.06%.

Reported Earning Dates

CDXS is expected to report earnings on Jul 31, 2025.

EPIX is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-0.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDXS($185M) has a higher market cap than EPIX($74.1M). EPIX YTD gains are higher at: -6.704 vs. CDXS (-53.249). EPIX has higher annual earnings (EBITDA): -27.4M vs. CDXS (-62.28M). EPIX has more cash in the bank: 114M vs. CDXS (59.8M). EPIX has less debt than CDXS: EPIX (280K) vs CDXS (59.5M). CDXS has higher revenues than EPIX: CDXS (49.8M) vs EPIX (0).
CDXSEPIXCDXS / EPIX
Capitalization185M74.1M250%
EBITDA-62.28M-27.4M227%
Gain YTD-53.249-6.704794%
P/E RatioN/AN/A-
Revenue49.8M0-
Total Cash59.8M114M52%
Total Debt59.5M280K21,250%
FUNDAMENTALS RATINGS
CDXS vs EPIX: Fundamental Ratings
CDXS
EPIX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
14
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
8962
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EPIX's Valuation (14) in the Pharmaceuticals Major industry is in the same range as CDXS (44) in the Chemicals Specialty industry. This means that EPIX’s stock grew similarly to CDXS’s over the last 12 months.

EPIX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that EPIX’s stock grew similarly to CDXS’s over the last 12 months.

EPIX's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as CDXS (98) in the Chemicals Specialty industry. This means that EPIX’s stock grew similarly to CDXS’s over the last 12 months.

EPIX's Price Growth Rating (62) in the Pharmaceuticals Major industry is in the same range as CDXS (89) in the Chemicals Specialty industry. This means that EPIX’s stock grew similarly to CDXS’s over the last 12 months.

EPIX's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that EPIX’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSEPIX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 6 days ago
85%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 27 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 3 days ago
70%
Aroon
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EPIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRJIX10.890.03
+0.28%
Morgan Stanley Multi-Asset Real Return I
ASCLX12.98-0.08
-0.61%
AB Select US Long/Short C
IPETX6.16-0.06
-0.96%
Voya Large Cap Value Port S2
LAAFX19.24-0.19
-0.98%
Lord Abbett Affiliated F
TLAFX11.30-0.17
-1.48%
Transamerica Large Core ESG R4

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
-0.89%
DNLI - CDXS
52%
Loosely correlated
-2.51%
PRAX - CDXS
49%
Loosely correlated
-1.62%
BEAM - CDXS
46%
Loosely correlated
-2.18%
CRBU - CDXS
45%
Loosely correlated
-4.31%
ABCL - CDXS
45%
Loosely correlated
+1.59%
More

EPIX and

Correlation & Price change

A.I.dvisor indicates that over the last year, EPIX has been loosely correlated with LXRX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if EPIX jumps, then LXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EPIX
1D Price
Change %
EPIX100%
-1.76%
LXRX - EPIX
34%
Loosely correlated
-3.49%
ELAB - EPIX
31%
Poorly correlated
-4.15%
CDXS - EPIX
25%
Poorly correlated
-0.89%
ERAS - EPIX
23%
Poorly correlated
-3.27%
BIVI - EPIX
23%
Poorly correlated
-4.20%
More